chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Developed a rash on both arms that he still currently has; This is a spontaneous report from a contactable consumer (patient's wife). An adult male patient (age 57, units: not provided) received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, lot Number and expiration date was unknown), via an unspecified route of administration on 15May2021 as single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, lot number unknown and expiration date was unknown), via an unspecified route of administration on an unspecified date, as single dose for covid-19 immunization. On an unspecified date in May2021, after second dose of vaccine patient developed a rash on both arms that he still currently has. The outcome of the event was reported as not recovered.    Information about batch/Lot number has been requested.
1200 vaccine administered 1230 c/o lips tingling 1237 25 mg Benadryl po given 1245 lips continue to tingle, c/o itching all over body SAO2 95% on room air. Benadryl 25 mg po given. Breathing without diffuculty 1252 c/o still itching sao2 98%, HR 88, Resp 18, lungs clear 1334 99.7, Resp 18,HR 84 c/o itchy lips and tongue tingling, lungs clear 1356 Epi administered into Rt thigh B/P 140/60, 97.7, HR 82, Resp 18 1402 C/o feeling jittery, lips not tingling SAO2 99.0  1415 160/78  resp 18, tip of tongue tingling, itching gone 1423 Discharged to home. Ambulatory. Instructed to follow up with PCP. Verbalized understanding
Patient received 2nd dose of Pfizer on 01/13/2021. Patient particpates in weekly Covid testing through Health Systems Care Center and tested positive for COVID-19 on 09/02/2021.
Chill; Sore arm; Fever; Diarrhea; This is a spontaneous report from a non-contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 23Apr2021 at 13:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously received penicillin V potassium (MANUFACTURER UNKNOWN), ciprofloxacin (MANUFACTURER UNKNOWN) and metronidazole hydrochloride (MANUFACTURER UNKNOWN) and had drug allergy. On 23Apr2021 at 16:00, the patient experienced chill, sore arm, fever and diarrhea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events, chill, sore arm, fever and diarrhea was not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Zoster on left arm on 2/11/02; treated with Acyclovir.
Pt complained of dizziness for 2 weeks prior to hospitalization 4/10/2021, and passed out 6 times in the 2 days prior to admission.  Upon admission was found to have acute pulmonary embolism.  Physician requested VAERS report.
I got this shot and a few days later I started experiencing debilitating pain in my right arm and shoulder. My upper arm and shoulder now regularly locks up at night, to the point where I have to use my left arm to move my right arm. The pain is so bad that it regularly wakes me up at night. It is difficult to get dressed. I still experience the pain today.
Information has been received from a nurse concerning a 13 year old female patient who on 17-MAR-2007 was vaccinated with a dose of Gardasil, lot #655619/1427F. The nurse reported that she noticed that the syringe was leaking, and she couldn't quantify how much vaccine was received. She added that several minutes after the injection, the patient felt a bit faint, but recovered with no specific intervention. No further information is available.
Received her 2nd dose of the covid vaccine on 1/8/2021. No side effects all weekend. Woke up on 1/11/2021with systemic hives, rashes that itch. Denies prior reaction to previous variance dose #1 on 12/18/2020. Denied any difficulty breathing or SOB. Took 25 mg of Benadryl this am and then called PCP who is a OB who said to take 50 mg of Bendery and if symptoms do not improve go to Urgent Care.  Follow-up call made by provider 1816: Employee reported going to Urgent Care where she recieved Soulmedrol IM and an AB test. Hives covering entire body and scalp.
Day 1-2, very sore arm Day 3-4, slightly itchy Day 5-7, raised bump (like hive), warm and itchy Day 8+, swollen upper arm, hard, hot, itchy, painful
like a ball's eye red inflammation on the arm where the first dose of the vaccine was injected; like a ball's eye red inflammation on the arm where the first dose of the vaccine was injected; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (159558). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 25Feb2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE INFLAMMATION (non-serious), VACCINATION SITE ERYTHEMA (non-serious) all with onset 05Mar2021, outcome "unknown" and all described as "like a ball's eye red inflammation on the arm where the first dose of the vaccine was injected".  Additional information: The reporter asked if it was okay to get the Covid -19 vaccine second dose scheduled on 25Mar2021 be injected on the same arm as with the first dose of the vaccine given on 25Feb2021 even though she had a very rare side effect 8 days after. She had like a ball's eye red inflammation on the arm where the first dose of the vaccine was injected but she still wanted to get the second dose of the vaccine injected on the same arm.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
muscle pain, burning sensation and falling off, terrible pain in his muscles; joint pain; soreness in his mouth, burning inside his mouth; Rash; This spontaneous case was reported by a consumer and describes the occurrence of ORAL PAIN (soreness in his mouth, burning inside his mouth), RASH (Rash), ARTHRALGIA (joint pain) and MYALGIA (muscle pain, burning sensation and falling off, terrible pain in his muscles) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Feb-2021, the patient experienced RASH (Rash). On 13-Feb-2021, the patient experienced ORAL PAIN (soreness in his mouth, burning inside his mouth). On 22-Feb-2021, the patient experienced ARTHRALGIA (joint pain). On 26-Feb-2021, the patient experienced MYALGIA (muscle pain, burning sensation and falling off, terrible pain in his muscles). On 11-Feb-2021, RASH (Rash) had resolved. At the time of the report, ORAL PAIN (soreness in his mouth, burning inside his mouth), ARTHRALGIA (joint pain) and MYALGIA (muscle pain, burning sensation and falling off, terrible pain in his muscles) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment and concomitant medicines were not included  Action taken with mRNA-1273 in response to the event was unknown
Dizziness; Vertigo; Headache; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the right arm on 31Mar2021 at 08:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy. Concomitant medications included cetirizine hydrochloride (ZYRTEC), ibuprofen (MANUFACTURER UNKNOWN) and multi vitamin (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccine within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via an unspecified route of administration in the left arm on 10Mar2021 at 09:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 03Apr2021, the patient experienced dizziness, vertigo and headache. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with meclizine. The clinical outcome of the events dizziness, vertigo and headache were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Breakthrough COVID case. Incidental finding on screening on admission. Asymptomatic. Tested positive 08/08/2022.
10/23/00, telephone call from mom, to report that pt woke up with a swollen face on Saturday AM which continued through the weekend. Also complained of severe itching around mouth and eyes.
Patient came in for PREVNAR 13. Patient didn't realize they already received PREVNAR 13 at MD's office in January.
third dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of EXTRA DOSE ADMINISTERED (third dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was provided by the reporter.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXTRA DOSE ADMINISTERED (third dose). At the time of the report, EXTRA DOSE ADMINISTERED (third dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment details were reported.   Reporter did not allow further contact
~5-7 following the administration of VZV, MMR, and DTaP vaccines he developed a symptoms c/w Henoch Schonlein purpura.
Itching that broke out into rash on back, chest, face and neck. Symptoms started 1-2 hrs after receiving vaccine.
Tested positive 15 June 2022. Low grade fever, congestion, cough, achy and fatigue.  Doctor visit for cough resulted in 2 inhalers and pearls prescriptions. 10 weeks later I still have cough.
Felt light headed, nausea.  Tepm and BP fine. Juice drink given and laid down.  Sent home with mom.  Drank g-ale and soup.  Slept for 3 hours. Felt better when woke.  Felt fine the next day.  No medical care needed.
Cold symptoms started 9-7-08. On 9-9-08 started with generalized pain in arms, legs, buttocks. Pain especially severe in hips and legs. Pain was so severe on 9-9-08 that parent took child to E.R.
sore arm,  fever 101 , chills, and aching muscles, flu like symptons
Initial and follow up information has been received from a licensed practical nurse, a physician and the patient's mother, concerning a "4 weeks old" male with no pertinent medical history and no known drug allergies who on 10-JAN-2011 was vaccinated with pediatric VAQTA, s-dose, 25u, "injection". There was no concomitant medication. On 10-JAN-2011, the patient was vaccinated the pediatric VAQTA instead of the Hep B. by a nurse in doctor's office. Initial report was reported on 10-JAN-2011 by a nurse, no adverse event. On 11-JAN-2011, the patient's mother described his son experienced sleeping more not really eating since he had gotten the vaccination 10-JAN-2011. She was not sure what the name of the vaccine was but told it was a Merck vaccine. The symptom was not recovered at the time of reporting. Follow up report was reported on 11-JAN-2011 4:35 pm by physician, said the patient experienced cranky, irritable and not eating well after vaccination, and the child recovered on 11-JAN-2011. The patient sought medical attention via office visit. No lab diagnostics studies performed. Additional information has been requested.
Significant swelling from shoulder to elbow "twice normal size", redness, hot to touch, pain/very tender to the touch, itchy at times. Symptoms started within a couple hours of injection. Started to improved 5/24/16.
Note: Any requests for follow-up information on this case should be sent directly to the sponsor of this study, Sanofi Pasteur. This study case was received from the investigator in a trial on 21 January 2014. An 33 year-old male subject whose past medical history included high blood pressure, elevated cholesterol and shortness of breath was found to have "other, carditis" 18 days after receiving on 30 August 2013 an injection of ACAM2000 (lot number, route and site of administration not reported). The subject had a normal echocardiogram on 01 October 2013. ECG results were not available. Troponin I, Lumbar puncture and MRI of the brain, spinal cord and heart were not performed. Treatments were not reported. Additional information will be requested from the investigator. The subject's outcome was not reported. Note: There is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Documents held by sender: none.
Redness, itching, and swelling around injection site 12-18 hours after vaccines given.
injuries resulting from Zostavax use: Herpes Zoster; Herpes Zoster; products liability - defective design; manufacturing defect; Information has been received from a lawyer regarding a case in litigation concerning a currently 68 years old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.  The patient was prescribed the Zoster Vaccine Live (ZOSTAVAX) vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 15-FEB-2016, the patient was administered zoster vaccine live(ZOSTAVAX) (dose, route of administration, anatomical location, lot#, expiration date were unknown) by a pharmacist. On an unknown date, the patient was treated by a nurse practitioner for the following injuries resulting from the patient's Zoster Vaccine Live (ZOSTAVAX) use: Herpes Zoster.  The patient claimed damages as a result of: Injury to themselves; Economic losses.  The following claims were asserted: negligence; products liability - defective design; products liability - manufacturing defect; products liability-failure to warn; breach of express warranty; breach of implied warranty; fraudulent misrepresentation; fraudulent concealment; negligent misrepresentation; unjust enrichment; strict liability; consumer fraud; punitive damages.  The outcome of the event was unknown. Causality assessments were related.
Erythematous papular lesions on upper torso, back and a few on the scalp. 1 lesion on forehead. SPV on 3/14/03, lesions noted 2 days ago. Some are pruritic.
Extreme back pain. Burning pulsating pain in all joints. Tingling in wrists, ankles and legs. Fever, chills, muscle pain and swollen lymph nodes.
within 5-10 min, full body rash, itching, nausea, headache, several hives on trunk
Itching at the injection site that seems to worsen during the night time; Intense arm pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Intense arm pain) and VACCINATION SITE PRURITUS (Itching at the injection site that seems to worsen during the night time) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Mar-2021, the patient experienced PAIN IN EXTREMITY (Intense arm pain). On 16-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (Itching at the injection site that seems to worsen during the night time). At the time of the report, PAIN IN EXTREMITY (Intense arm pain) and VACCINATION SITE PRURITUS (Itching at the injection site that seems to worsen during the night time) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.
This case was reported by a consumer via call center representative and described the occurrence of sickness in a patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced sickness. On an unknown date, the outcome of the sickness was recovered/resolved. It was unknown if the reporter considered the sickness to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient stated that, SHINGRIX made the patient terribly sick for three days. The patient had to get the second dose and wondered if the patient was likely to experience the same side effects after 2nd dose. The patient was told, they would be contacted back by product specialist.
This spontaneous report as received from a pharmacist refers to a 66 year old female patient. Her relevant medical history includes suffering an intra-parenchymal and subarachnoid hemorrhage and hospitalization in an Intensive Care Unit (ICU). Her relevant past drug history was unknown. On 28-FEB-2015, the patient was vaccinated with the first dose of PNEUMOVAX 23 in the right deltoid, lot number K018528 expiration date 14-APR-2016. Her relevant concomitant medications included PROTONIX and maintenance fluids. Two days later, on 02-MAR-2015, while being transferred from the ICU to the medical-surgical floor of the hospital, she was inadvertently given a second dose of PNEUMOVAX 23, the lot number and expiration date for the second dose was not known by the pharmacist. There was no relevant laboratory data. As of 02-MAR-2015, she no longer takes PNEUMOVAX 23 and the outcome of mistakenly being given a second dose of PNEUMOVAX 23 within two days of the first dose was unknown at the time of the report. Additional information has been requested.
Engerix-B pediatric dose to adult patient; Engerix-B pediatric dose to adult patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of underdose in a 37-year-old female patient who received HBV (Engerix B pediatric) (batch number 3T5L9, expiry date 09-MAR-2025) for prophylaxis.   On 15-SEP-2023, the patient received Engerix B pediatric. On 15-SEP-2023, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: Engerix-B pediatric dose to adult patient) and adult use of a child product (Verbatim: Engerix-B pediatric dose to adult patient).  The outcome of the underdose and adult use of a child product were unknown.   Additional Information: GSK receipt date: 15-Sept-2023 The case was reported by a nurse.  The reporter consented to follow up via email. A pediatric dose of Engerix-B was administered to an adult patient, which led to underdose and adult use of a child product.
Within 24 hours developed "temporal" headache and has headaches off and on since vaccination...Relates temporal area is tender to touch and he has never had this type of headache before Relates he did call his physician but did not go in for a visit Relates he has had to take some otc for relief of headache twice since the headaches started He does not plan to take second dose at this time
After the 2nd dose on the 27th, the vertigo after that was not too bad and it had kind of gone away a little bit and then two weeks after that, April 11, I had the worst vertigo I've had the whole time to a point where I cancelled appointments on April 12. I continued going to my chiropractor and it helped a little bit but not enough, so I scheduled an appointment with an ENT and went for my first appointment on May 7 and he proceeded to do an Epley procedure to try and correct the vertigo, and it helped somewhat but on May 24 I had another pretty major episode and ended up scheduling another appointment with the the Doctor for June 11. On June 4, I had a really major vertigo episode and I went back to the ENT on June 11, and he said there wasn't anything they could do for it, and gave me an exercise I could do, and I have had vertigo on and off since then. I continued seeing my chiropractor and I also have seen my PCP and I may try some vertigo therapy.
After receiving her MMRV vaccine at her 1 year appt., patient experienced a slight fever, we kept the fever down and associated it with shots like normal. However, 2-3 days later, patient began to exhibit spots, and a full body rash, we brought her back into the Dr. and they said that she was "showing" and that it wasn't uncommon and would go away. After a week or 2 of the rash, patient began to blister and get pustules on top of the rash, we again took her into the Dr. where we were told she was continuing to "show" and that there was a small percentage of children who would do this... about a week later, she began to get swollen lymphnodes and overall body aches. We took her back in to the Dr. and he confirmed that there was nothing we could do but to wait it out. This all went on from the end of October 2018 until the end of January 2019.
Bell's Palsy/developed sudden left-sided facial paralysis with notable facial droop and headache; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unspecified age. Information about the patient's concurrent condition, concomitant medication or medical history was not provided. On or around 08-DEC-2011 the patient was vaccinated with zoster vaccine live(ZOSTAVAX) (strength, dose, route, lot # and expiration date were not reported) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unspecified date (reported as shortly after the vaccination, unsure it's in December 2011 or 2012), the patient developed sudden left-sided facial paralysis with notable facial droop and headache. He presented to the emergency room, was diagnosed with Bell's Palsy and prescribed valacyclovir (VALTREX) with a prednisone taper. The patient continued to seek treatment and follow up care with a neurologist for ongoing facial asymmetry symptom's as a result of the Bell's Palsy. As the result of vaccine live(ZOSTAVAX), the patient suffered severe, serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. He also suffered medical expenses, the loss of accumulations and other economic and non-economic damages. The outcome of Bell's Palsy was not recovered. The reporter considered the event to be disable and related to Zoster Vaccine Live(ZOSTAVAX). Upon internal review, Bell's Palsy was determined to be medically significant.